Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lamaur

This article was originally published in The Rose Sheet

Executive Summary

New hairstyling line distributed through TV shopping network will launch in June in Canada and in the U.S. in July, Lamaur says May 18. Collection is among various licensing deals planned to drive growth (1"The Rose Sheet" April 9, p. 7). First quarter net revenues declined 33.8% to $6.1 mil. due to $1.5 mil. reduction related to manufacturing divestiture and $314,000 retail sales decline due to discontinued low margin items, Lamaur says. Losses totaled $783,000, versus loss of $463,000 in first quarter 2000. Start-up expenses of B In10se hair care negatively affected profits, company reports

You may also be interested in...



Lamaur Licensing Agreements Represent New Growth Channels

Hair care manufacturer Lamaur plans to sign a number of exclusive licensing agreements during the upcoming year to drive business in new, uncharted directions, as the Fridley, Minn. company continues to rebuild a struggling business.

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands

Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle

Latest Headlines
See All
UsernamePublicRestriction

Register

RS009266

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel